Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mast cell immunoglobulin-like receptor 1 (MILR1), also known as Allergin-1, is a transmembrane inhibitory receptor primarily expressed on mast cells[1][2][6]. This receptor belongs to the immunoglobulin superfamily and operates by negatively regulating IgE-mediated mast cell activation, thereby suppressing degranulation and limiting type I immediate hypersensitivity responses (allergic reactions)[1][2]. MILR1 is localized at the plasma membrane where it functions as a cell surface signaling receptor[1][2]. It has potential relevance in allergic diseases, mitochondrial disorders, and variable expression across cancer tissues, although its role as a direct therapeutic drug target remains under investigation[1][4][6].
Drugs would act by modulating receptor function to regulate mast cell activation (hypothetical, specific clinical drugs not listed in current sources)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mast cell immunoglobulin-like receptor 1 (MILR1).